Los Angeles, December 9, 2021— Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the first patient cohort completed their full dose cycle with no serious adverse events (SAEs) in its multi-site Phase 1 oncology trial. The safety and tolerability of TRE-515, a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK) […]
Los Angeles, November 12, 2021— Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515 for the treatment of optic neuritis (ON). ON is a rare autoimmune disease where patients rapidly lose vision in one or both eyes with 1 in 10 patients never fully recovering their eyesight. TRE-515 is a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK). […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Trethera Supporthttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera Support2021-11-15 03:37:462021-12-14 16:50:58Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis
Los Angeles, October 15, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the first patient has been treated with TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK). Trethera’s multi-site Phase 1 study will evaluate TRE-515 monotherapy in up […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Trethera Supporthttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera Support2021-10-14 23:44:052021-12-14 16:52:59Trethera Doses First Patient in Landmark Clinical Trial for the Treatment of Solid Tumors With First-In-Class Drug TRE-515
Los Angeles, May 25, 2021 – Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancers and autoimmune diseases, is pleased to announce the appointment of renowned autoimmunity researcher Dr. Larry Steinman to its Scientific Advisory Board. Dr. Steinman will be advising Trethera regarding TRE-515 development, a first-in-class compound with the potential to treat multiple sclerosis (MS) and other autoimmune neurologic diseases. […]
Los Angeles, April 19, 2021— Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has approved its TRE-515 investigational new drug (IND) application for the treatment of solid tumor malignancies. Trethera will […]
Safety Review Committee Advances Trethera Phase 1 Solid Tumors Trial to Next Dose After First Patient Cohort Achieves Primary Endpoint
/in News /by Trethera SupportLos Angeles, December 9, 2021— Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the first patient cohort completed their full dose cycle with no serious adverse events (SAEs) in its multi-site Phase 1 oncology trial. The safety and tolerability of TRE-515, a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK) […]
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis
/in News /by Trethera SupportLos Angeles, November 12, 2021— Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515 for the treatment of optic neuritis (ON). ON is a rare autoimmune disease where patients rapidly lose vision in one or both eyes with 1 in 10 patients never fully recovering their eyesight. TRE-515 is a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK). […]
Trethera Doses First Patient in Landmark Clinical Trial for the Treatment of Solid Tumors With First-In-Class Drug TRE-515
/in News /by Trethera SupportLos Angeles, October 15, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the first patient has been treated with TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK). Trethera’s multi-site Phase 1 study will evaluate TRE-515 monotherapy in up […]
Globally Recognized Multiple Sclerosis Expert, Dr. Lawrence “Larry” Steinman, Joins Trethera Scientific Advisory Board
/in News /by Trethera SupportLos Angeles, May 25, 2021 – Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancers and autoimmune diseases, is pleased to announce the appointment of renowned autoimmunity researcher Dr. Larry Steinman to its Scientific Advisory Board. Dr. Steinman will be advising Trethera regarding TRE-515 development, a first-in-class compound with the potential to treat multiple sclerosis (MS) and other autoimmune neurologic diseases. […]
Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy
/in News /by Trethera SupportLos Angeles, April 19, 2021— Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has approved its TRE-515 investigational new drug (IND) application for the treatment of solid tumor malignancies. Trethera will […]